MedTrace Logo

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

NCT02101281 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

The primary objective of this study was to assess the efficacy and safety of different doses of rhNGF when administered as eye drops to patients with dry eye.

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

rhNGF 20 µg/mL

1 drop for each eye, twice daily for 28 day

DRUG

rhNGF 4 µg/mL

1 drop each eye, twice daily for 28 day

Sponsors & Collaborators

  • Cross Research S.A.

    collaborator INDUSTRY

  • Dompé Farmaceutici S.p.A

    lead INDUSTRY

Principal Investigators

  • Gerhard Garhöfer, MD · Medical University of Vienna, Vienna General Hospital, AKH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-20
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02101281 on ClinicalTrials.gov